ArticleFrontiers in immunology2026
FGF2 alleviates LPS-induced acute lung injury by inhibiting ferritinophagy-mediated ferroptosis in AT2 cells via the Hippo-YAP signaling pathway.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adenine nucleotide translocase 2 (ANT2) deficiency reprograms ferroptosis in alveolar progenitor cells to promote emphysema.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ferroptosis of type II alveolar epithelial (AT2) cells plays a crucial role in the pathological progression of acute lung injury (ALI). Although fibroblast growth factor-2 (FGF2) has been shown to exert protective effects against ALI, the underlying mechanisms remain largely unexplored. Methods: The present study investigated the relationship between ferroptosis and FGF2 in the pathogenesis of ALI. Results: Our study found that FGF2 administration mitigated lung pathology, respiratory dysfunction, inflammation, and oxidative stress induced by lipopolysaccharide (LPS). Conversely, genetic knockout of FGF2 exacerbated lung injury, inflammation, oxidative stress, and ferroptosis. RNA sequencing and bioinformatics analyses identified ferroptosis as a key target of FGF2-mediated protection. Pharmacological induction of ferroptosis negated the protective effects of FGF2 on AT2 cells. Mechanistically, co-immunoprecipitation assays revealed that FGF2 suppressed ferritinophagy-associated changes by disrupting the interaction between NCOA4 and FTH1. Further investigation revealed that FGF2 modulated this interaction via the Hippo-YAP signaling pathway. Conclusion: Collectively, these results underscored the therapeutic potential of targeting the FGF2-mediated suppression of ferritinophagy-induced ferroptosis in treating LPS-induced ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.